LYTIX.OL

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$13M	+638.2%	$-1.35	$-1.35–$-1.35	—	1
2027	$84M	+568.1%	$-1.36	$-1.36–$-1.36	—	1
2028	$36M	-57.5%	$-1.43	$-1.43–$-1.43	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$0.11

Price

$8.50

Implied downside

-99%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
LYTIX.OLLytix Biopharma AS	$8.50	+0.00%	$654M	—
ABS.OLArctic Bioscience AS	$2.79	+3.33%	$75M	—
BGBIO.OLBerGenBio ASA	$1.17	+0.00%	$46M	—
CONTX.OLContextVision AB (publ)	$4.50	+3.93%	$335M	—
GENT.OLGentian Diagnostics AS	$38.50

Lytix Biopharma AS

Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.

www.lytixbiopharma.com

Employees: 14
IPO / List date: Jun 14, 2021
HQ: NO

Held by traders on TradeandTell

No one on the platform currently holds LYTIX.OL.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in LYTIX.OL as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded LYTIX.OL yet.